F
Fred D. Lublin
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 334
Citations - 54203
Fred D. Lublin is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Multiple sclerosis & Natalizumab. The author has an hindex of 63, co-authored 316 publications receiving 47075 citations. Previous affiliations of Fred D. Lublin include Corinne Goldsmith Dickinson Center for Multiple Sclerosis & University of Delaware.
Papers
More filters
Journal ArticleDOI
Magnetic resonance imaging of meningoradiculomyelitis in early disseminated Lyme disease.
TL;DR: The authors present the clinical and radiographic findings, both before and after treatment, in a patient with meningoradiculomyelitis due to early disseminated Lyme disease.
Journal ArticleDOI
Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis.
Marcus W. Koch,Jop P. Mostert,Jerry S. Wolinsky,Fred D. Lublin,Bernard M. J. Uitdehaag,Gary Cutter +5 more
TL;DR: In this paper, the authors compared the Expanded Disability Status Scale (EDSS) to the T25FW and NHPT in a large RRMS randomized controlled trial (RCT) dataset.
Journal ArticleDOI
When marketing and science intersect Do patients with MS benefit
TL;DR: Although MS entered the treatment era a scant 9 years ago with US Food and Drug Administration approval of interferon β-1b, since then, two amino acid polymer, glatiramer acetate; and a chemotherapeutic agent, mitoxantrone, have received regulatory approval in the United States and many other countries for various forms of relapsing MS.
Journal Article
Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b [2] (multiple letters)
A. Frese,F. Bethke,Peter Lüdemann,Florian Stögbauer,Placido Bramanti,Edoardo Sessa,Carmela Rifici,Giangaetano D'Aleo,D. Floridia,P. Di Bella,Fred D. Lublin +10 more
TL;DR: Thirteen of the 19 patients treated with IFNβ-1b had increased spasticity requiring increased antispasticity drug administration, which suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.
Journal ArticleDOI
Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.
Fred D. Lublin,Stacey S. Cofield,Gary Cutter,Tarah Gustafson,Stephen Krieger,Ponnada A. Narayana,Flavia Nelson,Amber Salter,Jerry S. Wolinsky +8 more
TL;DR: Combining GA & IFN did not produce a significant clinical benefit over the entire study duration, and both the combination therapy and GA were significantly better than IFN in reducing the risk of relapse.